How A Drugmaker Gamed The System to Keep Generic Competition Away

Favicon WLRN

When Celgene Corp. first started marketing the drug Revlimid to treat multiple myeloma in 2006, the price was $6,195 for 21 capsules, a month's supply. By the time David Mitchell started taking Revlimid in November 2010, Celgene had bumped the price up to about $8,000 a month. When he took his last month's worth of pills in April 2016, the sticker price had reached $10,691. By last March, the list price had reached $16,691 . Revlimid appears to have caught the attention of Health and Human Services Secretary Alex Azar who used it as an example Wednesday — without naming it outright — of ho...

Read the full article here: WLRN


The post: «How A Drugmaker Gamed The System to Keep Generic Competition Away » has been published on the website WLRN where, everyday, you can find the latest news about Miami's area.



Get more articles about this topic

Leave a comment